ArticleFrontiers in pharmacology2026
A universal fluorescent sensing platform based on "signal switching induced by enzyme catalyzed substrate hydrolysis" for high-throughput discovery of xanthine oxidase inhibitors from traditional Chinese medicine.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Traditional Chinese medicine (TCM) serves as the treasure house for discovering lead compounds in drug development, demonstrating significant potential in the creation of anti-gout agents. However, given the complexity of TCM, conventional detection methods not only were susceptible to interference from metabolites but also suffered from low throughput, thereby hindering the efficient screening of inhibitors. Methods: This study developed a universal fluorescent sensing platform based on the principle of enzyme specific substrate recognition for the high-throughput screening of xanthine oxidase (XOD) inhibitors. Results: This approach offered two advances: (1) Interference-resistant detection: for screening in the complex system of TCM, its high emission wavelength (λem = 690 nm > 680 nm) and larger Stokes shift (Δλ = 148 nm) further enhanced anti-interference capability. (2) High-throughput screening capacity: by integrating HPLC-fully automatic partial fraction collector (HPLC-FC) and UHPLC-Q-TOF/MS, we established an "isolation-detection-identification" platform, screening and identifying four XOD inhibitors (Quercetin-3-sambubioside, Hyperoside, Isoquercitrin and Astragalin) from Nelumbinis Folium (NF) extract, with their combined inhibitory contribution accounting for 61.22% of the total inhibition activity. Discussion: Therefore, this strategy provided a powerful methodological tool for the high-throughput discovery of next-generation XOD inhibitors from TCM. And it offers a universal paradigm for the high-throughput discovery of bioactive metabolites from TCM targeting different diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.